background pattern

Creating novel therapeutics
for patients with excellent expertise
in kinase inhibitors

 
PIPELINE

A precisely crafted pipeline, accelerating the pace of drug discovery.

With hundreds of thousands of experimental data points and robust target validation, Voronoi rapidly identifies and optimizes promising drug candidates. Discover how innovation unfolds in our pipeline.

 
Publications

Science with purpose.

From design to clinic delivering targeted therapies that matter. Explore our research and breakthroughs.

background pattern
OUR Approach

VORONOMICS-Based Drug Design

VORONOMICS, a proprietary platform, revolutionizes the drug development process, enabling the rapid discovery of development candidates with exquisite selectivity and brain penetration that are unprecedent.

Careers

Science moves faster when we move together.
we turn collaboration into discovery.

bg-our-mission-left bg-our-mission-right
Voronoi Team
Voronoi Team
Voronoi Team
Voronoi Team
Voronoi Team

Work and enjoyment come together naturally

with spontaneous connections that make collaboration flow, in a space full of energy, ideas, and deep focus.
We experience both concentration and genuine joy, from sleek,
comfortable labs that foster scientific immersion to casual ping-pong matches and quick energy boosts at the snack corner at Voronoi.

Join our team

Latest Highlights

AACR-NCI-EORTC International Conference 2025

Voronoi is excited to participate in the AACR-NCI-EORTC 2025

  • calendar icon Date & Time: Oct 22-26, 2025
  • location icon Location: Hynes Convention Center, Boston, Massachusetts

Latest News

  • 2025.04.28
보로노이 VRN11, 저용량에서 EGFR C797S 뇌전이 비소세포폐암 환자 대상 효능 입증

보로노이가 미국암학회(AACR2025)에서 공개한 EGFR 비소세포폐암 표적치료제 VRN11의 임상 초기 데이터를 통해 EGFR C797S 돌연변이 환자 대상으로 효능을 입증하였다

  • 2025.03.26
보로노이, ‘VRN10’ 국내 임상 1상 IND 승인

보로노이는 우리나라 식품의약품안전처(식약처)로부터 HER2 양성 고형암 치료제인 VRN10 의 임상1상 임상시험계획(IND)을 승인받았다고 밝혔다.